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Aims: Monocytes/macrophages play a crucial role in the development, progression,
and complication of atherosclerosis. In particular, foam cell formation driven by
CD36 mediated internalization of oxLDL leads to activation of monocytes and
subsequent release of microvesicles (MVs) derived from monocytes (MMVs). Further,
pro-inflammatory leukotriene B4 (LTB4) derived from arachidonic acid promotes
atherosclerosis through the high-affinity receptor BLTR1. Thus, we aimed to investigate
the correlation between different MMV phenotypes (CD14+ MVs) on the one hand, and
arachidonic acid and eicosapentaenoic acid contents in different compartments including
atherosclerotic plaques, plasma, and granulocytes on the other.
Methods and Results: Samples from patients with femoral atherosclerosis and
healthy controls were analyzed on an Apogee A60 Micro-PLUS flow cytometer.
Platelet-poor plasma was labeled with lactadherin-FITC, anti-CD14-APC, anti-CD36-PE,
and anti-BLTR1-AF700. Eicosapentaenoic acid and arachidonic acid content in different
compartments in patients were analyzed using gas chromatography. Compared to
controls, patients had lower levels of BLTR1+ MVs (p = 0.007), CD14+BLTR1+ MVs
(p = 0.007), and CD14+BLTR1+CD36+ MVs (p = 0.001). Further, in patients CD14+
MVs and CD14+CD36+ MVs correlated inversely with arachidonic acid in granulocytes
(r = −0.302, p = 0.039 and r = −0.322, p = 0.028, respectively). Moreover,
CD14+CD36+ MVs correlated inversely with arachidonic acid in plasma phospholipids
in patients (r = −0.315, p = 0.029), and positively with triglyceride in both patients
(r = 0.33, p = 0.019) and controls (r = 0.46, p = 0.022).
Conclusion: This is the first study of its kind and thus the results are explorative
and only indicative. BLTR1+ MVs and CD14+CD36+ MVs has potential as markers of
atherosclerosis pathophysiology, but this needs further investigation.
Keywords: atherosclerosis, extracellular vesicles, microvesicles, BLT1, flow cytometry, arachidonic acid,
eicosapentaenoic acid, leukotriene b4 receptor
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INTRODUCTION
Despite thorough investigation of atherosclerosis, the initial
events that activate endothelial cells and circulating monocytes
are still debatable. Atherosclerosis is characterized by chronic
vascular inflammation, infiltration of lipid-laden macrophages,
and blood vessel narrowing (1). However, it has been shown
that pro-inflammatory mediators including TNF-α, IL-6, CRP,
and other factors present in atherosclerotic conditions stimulate
the formation of microvesicles (MVs). MVs are a heterogeneous
population of cell-derived membrane-encapsulated particles
ranging from 0.1 to 1.0µm in size released by outward budding of
the plasma membrane in latent, activated, stressed, and apoptotic
cells. They are characterized by a phosphatidylserine (PS) rich
outer membrane and by membrane proteins, receptors, and
cytosolic materials including mRNA and microRNAs from their
parental cell of origin giving an insight into the state of this
cell (2). For that reason, a growing interest acknowledging
the potential of MVs as biomarkers, in particular within
diseases associated with vascular injury, inflammation and
pro-thrombotic states has emerged and several studies have
demonstrated an elevation of MVs originating from monocytes
(MMVs) among others (3).
Another important player in the atherogenic process is the
scavenger receptor and fatty acid transporter CD36 (4). Binding
of oxidized low-density lipoprotein (oxLDL) and oxidized
phospholipids (oxPL) by CD36 expressed on macrophages leads
to internalization, foam cell formation and thickening of the
vessel wall media and intima (5). Further, it has been suggested
that polarization of pro-inflammatory macrophages underlying
the low-grade inflammatory state in atherosclerosis is driven by
CD36 exposure to oxLDL (6). In addition, binding of oxLDL
to CD36 stimulates secretion of cytokines attracting immune
cells that leads to further infiltration of intima and narrowing
of the vessel (4). Moreover, circulating CD36 shows a general
association with several cardio-metabolic conditions including
atherosclerosis (7). Thus, enumerating the level of MMVs
expressing CD36 may have the potential of detecting ongoing
atherosclerosis.
The risk of atherosclerosis has also been associated with the
intake of the marine n-3 polyunsaturated fatty acids (PUFAs),
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
and the more abundant n-6 PUFAs, linoleic acid and arachidonic
acid (AA) (8). Although pro-inflammatory leukotrienes (LTs) are
synthesized from both EPA and AA through the 5-lipoxygenase
pathway, LTs derived from EPA are much less potent than LTs
derived from AA with the most potent being LTB4 (8). The pro-
inflammatory signals are most likely promoted through the high-
affinity receptor BLT1 (BLTR1) and the low-affinity receptor
BLTR2 (9) and especially BLTR1 is suggested to be linked to the
development and progression of atherosclerosis as studies have
demonstrated that treatment with BLTR1 antagonists reduces
atherosclerotic lesions in mice (10). Thus, we expected that the
higher levels of LTB4 would increase the expression of BLTR1
and further activate BLTR1 expressing cells with higher levels of
circulating BLTR1+ MMVs as a consequence. Besides increasing
leukocyte/monocyte chemotaxis, binding of LTB4 to BLTR1
further enhances the expression of CD36 stimulating foam cell
formation (11). Therefore, we hypothesized that levels of CD36+
and BLTR1+ MMVs are increased in atherosclerotic patients, and
in particular in those with a high content of AA in granulocytes,
plasma, and plaques. The aim of this study was to investigate the
correlation between these MMV phenotypes on the one hand,
and AA and EPA contents in different compartments including
atherosclerotic plaques, plasma, and granulocytes on the other.
To clarify this we compared levels of different circulating MMV
phenotypes between participants with femoral atherosclerosis
and healthy controls and further compared the MMV levels with
the content of AA and EPA in the atherosclerotic participants.
Finally, we investigated the associations betweenMMV levels and
conventional risk factors of atherosclerosis. This might elucidate
the potential of CD36 and BLTR1 bearing MMV phenotypes as
novel biomarkers in predicting atherosclerosis.
METHODS
Study Population
This study included 48 participants (24 male/24 female) with
symptomatic peripheral arterial disease undergoing femoral
thrombendarterectomy as previously described (8) and 24
healthy controls (9 male/15 female, age >18 years). Exclusion
criteria for the participants with femoral atherosclerosis were
allergic asthma or rhinitis, systemic steroid treatment, chronic
inflammatory diseases, acute coronary syndrome within the last
30 days, cancer, and inability to give informed consent. Exclusion
criteria for the healthy participants were history of atherosclerotic
disease, hypertension, and medication of any kind.
Ethical Aspects
Ethical approval of the study was granted by the Research Ethics
Committee of the North Denmark Region (id. N-20100047). All
participants gave written informed consent in accordance with
the Declaration of Helsinki before inclusion.
Analysis of Leukotrienes and Fatty Acid
Composition in Atherosclerotic Plaques
and Plasma
Analyses of LTs and fatty acids in plaques have previously
been described by Nielsen et al. (8). Briefly, for LTB4
quantification, plaques removed during femoral artery
thrombendarterectomy were cut into smaller pieces and
stimulated with calciumionophore A23187 followed by a
solid phase immunoassay ELISA. Analyses of fatty acid
composition in plaques and granulocytes were performed using
gas chromatography as earlier described (8). The relative content
of fatty acids including PUFAs in plasma phospholipids was
analyzed by extraction of total lipids from plasma followed by
separation and gas chromatography analysis (8). The intake of
EPA and DHA was self-reported and only noted for the patients.
Preparation and Labeling of Samples for
MV Analysis
Blood samples for flow cytometric analysis were collected into
tubes containing sodium citrate anticoagulant at a 3.2% (0.105M)
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final concentration and centrifuged within 1 h after collection. To
obtain platelet-poor plasma (PPP) they were initially centrifuged
at 1,800x g for 10min at room temperature followed by
centrifugation of supernatant at 3,000x g for 15min and stored
at−80◦C until further analysis.
Upon analysis, freshly thawed PPP was vortexed shortly,
centrifuged at 1,850x g for 5min at room temperature
followed by fluorescent labeling. Twenty-five micro liter
centrifuged PPP was incubated for 30min at 4◦C in the dark
with 2.5 µL fluorescein isothiocyanate- (FITC-) conjugated
bovine lactadherin (83µg/mL, Hematologic Technologies Inc.,
Vermont, USA), 2.5 µL allophycocyanin- (APC-) conjugated
anti-human CD14 [200µg/mL, IgG1, κ (clone 63D3, BioLegend,
San Diego, CA, USA)], 2.5 µL phycoerythrin- (PE-) conjugated
anti-human CD36 [200µg/mL, IgG2α, κ, (clone 5-271,
BioLegend, San Diego, CA, USA)], and 2.5 µL Alexa Fluor 700-
(AF700-) conjugated anti-human BLTR1 [0.7 mg/mL, IgG2α,
(clone 2020/7B1, Novus Biologicals, USA)]. A second incubation
with matched isotype control antibodies were used as negative
controls. After incubation, samples were diluted in 390 µl or
1,665 µl 0.22-µm sterile filtered PBS to reach a final dilution
factor of 17 or 68.
Analysis of MVs by Dedicated
Small-Particle Flow Cytometry
Samples were analyzed using an A-60 Micro-PLUS
flow cytometer (Apogee Flow Systems, Hertfordshire,
United Kingdom). The sample flow rate was 0.75 µL/min
and the time of acquisition was 600 s for all samples. In order
to exclude excessive background noise a combined threshold on
light scatter and green fluorescence was set above background
using PBS and an un-labeled plasma sample, respectively.
Statistics from flow cytometry data was extracted and gating
was conducted as illustrated in Figure 1 in FlowJo version 10.4
(FlowJo LLC, Oregon, USA). First, the upper limit of the MV
gate was determined using size-calibrated green fluorescent silica
beads with the size of 1,000 nm and then applied to all samples
(Figures 1A,B). Second, MVs were defined as events within
the established size gate expressing PS indicated by binding
of lactadherin-FITC. Third, MVs originating from monocytes
were defined as CD14 positive events gated by log-scaled APC
fluorescence peak intensity (APC-H) at the 99th percentile of
isotypes (Figures 1C,D). Fourth, the MVs expressing CD36
and BLTR1 were defined as CD36 and BLTR1 positive events
on MVs and on the MMV subfraction gated by log-scaled
PE fluorescence peak intensity (PE-H) at the 99th percentile
of isotypes and log-scaled AF700 fluorescence peak intensity
(AF700-H) at the 99th percentile of isotypes, respectively
(Figures 1E–H).
Statistics
Statistical analyses were carried out using IBM SPSS Statistics
version 24.0 (SPSS, Armonk, NY) and GraphPad Prism 6.0
(GraphPad Software, La Jolla, California, USA). Categorical
FIGURE 1 | Flow cytometric gating strategy of MVs. (A) The MV gate was determined using size-calibrated green fluorescent silica beads with the size of 1,000 nm
and (B) applied to all samples. (C,D) Next, MMVs (CD14+) were gated by log-scaled APC fluorescence peak intensity (APC-H) at the 99th percentile of isotypes.
Finally, CD36+ MVs (E,F) and BLTR1+ MVs (G,H) were gated by log-scaled PE fluorescence peak intensity (PE-H) at the 99th percentile of isotypes and log scaled
AF700 fluorescence peak intensity (AF700-H) at the 99th percentile of isotypes, respectively.
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variables were compared with the Chi2 test. Continuous
variables were tested for normality and homoscedasticity by
Shapiro-Wilk’s W test and Levene’s test for equal variance,
respectively. Continuous variables were depicted as boxplots
with median and 25–75th percentiles (box) and 95% confidence
intervals (whiskers). Normally distributed data with equal
variances between groups were compared using Student’s
t-test. Heteroscedastic or non-normally distributed variables
were compared using the Mann-Whitney U-test. Statistical
correlations were analyzed in participants with femoral
atherosclerosis using Spearman’s ranked correlation analysis. All
p-values are two-sided, and statistical significance was defined as
p < 0.05.
RESULTS
Characteristics of the Study Population
The mean age for the 48 atherosclerotic patients and 24 controls
was 70.9± 10 and 47.1± 9.9 years, respectively. Both sexes were
represented with 50% males in the patient cohort and 60% males
in the control group. The median BMI was 25.2 ± 4.8 kg/m2 for
patients and 23.7 ± 3.2 kg/m2 for controls. The level of hsCRP
was almost two-fold higher in the patient cohort compared to the
control group (p < 0.015). Additional parameters are listed in
Table 1.
Patients Had Lower Levels of Circulating
BLTR1 Expressing MV Phenotypes
Compared to Controls
No significant differences in total MV concentration (p= 0.246),
CD14+ MVs (p = 0.277), CD36+ MVs (p = 0.656), and
CD14+CD36+ MVs (p = 0.115) between groups were observed.
Patients with femoral atherosclerosis had lower levels of BLTR1+
MVs (p = 0.007), CD14+BLTR1+ MVs (p = 0.007), and
CD14+BLTR1+CD36+ MVs (p = 0.001) compared to controls
(Figure 2). Age was not significantly correlated with any of the
investigated MV phenotypes in neither the patient cohort (rho
from −0.05 to −0.22, p from 0.13 to 0.74) nor the control group
(rho from−0.24 to 0.33, p from 0.11 to 0.88).
MMV Sub-phenotypes Correlated Inversely
With AA Content in Patients
Levels of CD14+ MVs and CD14+CD36+ MVs correlated
inversely with AA in granulocytes (r = −0.302, p = 0.039,
and r = −0.322, p = 0.028, respectively; Figures 3A,B).
CD14+CD36+ MVs further correlated inversely with AA in
plasma phospholipids (r = −0.315, p = 0.029; Figure 3C).
The level of CD14+ MVs and CD14+BLTR1+ MVs tended to
correlate inversely with AA in plasma phospholipids and AA in
plaques, respectively (r = −0.284, p = 0.050 and r = −0.291,
p = 0.058; Figures 3D,E). No correlations were identified
between MV level and content of EPA in plaques, granulocytes,
and plasma phospholipids as well as MV level and content of
LTB4 in plaques, granulocytes, and plasma phospholipids.
TABLE 1 | Baseline characteristics of study population.
Atherosclerotic
patients
Healthy
controls
p-value
(n = 48) (n = 24)
AGE AND GENDER
Age (years) 70.9 ± 10 47.1 ± 9.9 <0.001*
Sex (male/female) 24/24 9/15 0.452
Body mass index (kg/m2) 25.2 ± 4.8 23.7 ± 3.2 0.122
Current smokers (%) 35 17 0.168
MEDICAL HISTORY AND MEDICATIONS
Cardiovascular disease† (%) 58 – –
Diabetes mellitus (%) 24 – –
Aspirin treatment (%) 98 – –
Anti-hypertensive medication (%) 78 – –
Statin treatment (%) 96 – –
NSAID use‡ (%) 7 – –
EPA + DHA intake (g/day) 0.67 (0.32; 1.21) – –
LABORATORY EXAMINATION
Total cholesterol (mmol/l) 3.8 (3.4; 4.4) 5.05 (4.58; 5.45) <0.001*
LDL cholesterol (mmol/l) 1.75 (1.5; 2.1) 2.9 (2.48; 3.30) <0.001*
HDL cholesterol (mmol/l) 1.4 ± 0.42 1.71 ± 0.39 0.003*
Plasma triglyceride (mmol/l) 1.3 (1; 1.93) 1.0 (0.8; 1.2) 0.02*
Plasma glucose (mmol/l) 5.9 (5.5; 6.5) 5.35 (5.08; 5.8) <0.001*
Plasma hsCRP§ (mg/l) 1.8 (0.83; 4.67) 0.94 (0.67; 1.45) 0.014*
LTB4 in granulocytes (ng/107
cells)
203.0 ± 41.1 – –
LTB4 in plasma (pg/ml) 133.0 ± 108.2 – –
LTB4 in plaques (pg/mg) 5.4 ± 4.9 – –
AA in granulocytes (% of total
fatty acids)
13.1 ± 1.2 – –
AA in plasma (% of total fatty
acids)
10.5 ± 2.3 – –
AA in plaques (% of total fatty
acids)
6.4 ± 2.2 – –
EPA in granulocytes (% of total
fatty acids)
0.7 ± 0.3 – –
EPA in plasma (% of total fatty
acids)
2.1 ± 1.0 – –
EPA in plaques (% of total fatty
acids)
1.0 ± 0.4 – –
Data are depicted as mean ± SD or median (Q25%; Q75%). *Statistically significant
difference between patients and healthy controls.
†
Any diagnosis of stable angina,
unstable angina, MI, ischemic stroke, transitory ischemic attack or any procedure of
percutaneous coronary intervention or coronary artery bypass grafting. ‡Chronic use of
non-steroidal anti-inflammatory drugs (NSAID). §Patients with hsCRP > 10 mmol/l (n= 9)
were omitted since these values suggest acute rather than low-grade inflammation. Bold
values represents statistical significance.
MMVs Expressing CD36 Correlated With
Triglyceride Levels in Both Patients and
Healthy Controls
CD14+ MVs and CD14+CD36+ MVs correlated with plasma
triglyceride in both patients (r = 0.33, p = 0.022 and r = 0.34,
p = 0.019, respectively) and controls (r = 0.38, p = 0.063
and r = 0.46, p = 0.022, respectively). Furthermore, BLTR1+
MVs correlated with plasma triglyceride, and tended to correlate
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FIGURE 2 | (A–C) BLTR1+ MVs in atherosclerotic patients (n = 48, black) and healthy controls (n = 24, gray). Data are represented in MVs/µl and are depicted as
boxplots with whiskers as 95% confidence intervals.
inversely with LDL (r= 0.31, p= 0.028 and r=−0.27, p= 0.062,
respectively).
Effect of Elevated hsCRP on MV
Phenotypes in Patients
To investigate a possible effect of inflammation, MV phenotypes
from patients with hsCRP >10 mmol/l (N = 9) were compared
to patients with hsCRP ≤10 mmol/l (N = 39). No significant
differences were found in total MVs (p = 0.45), CD14+ MVs
(p = 0.98), CD36+ MVs (p = 0.21), BLTR1+ MVs (p = 0.76),
CD14+CD36+ MVs (p= 0.97), CD14+BLTR1+ MVs (p= 0.19),
and CD14+CD36+BLTR1+ MVs (p= 0.14).
DISCUSSION
This study was conducted to investigate the potential association
of circulating CD36+ and BLTR1+ MMVs with femoral
atherosclerosis on the one hand, and AA and EPA contents
in atherosclerotic plaques, plasma, and granulocytes on the
other.We hypothesized that patients with femoral atherosclerosis
would have higher levels of MMVs, in particular those expressing
CD36 and BLTR1, compared to healthy controls. We further
hypothesized that patients with high content of AA would have
associated elevated levels of these MMVs.
Unexpectedly, in the present study we found that the
concentration of total MVs, CD14+ MVs, CD36+ MVs, and
CD14+CD36+ MVs were not increased in the patient cohort
compared to healthy controls. Atherosclerosis is a chronic
inflammatory disease of the vessel wall and several studies have
shown that inflammation leads to increased leukocyte-derived
MV release (12). Further, circulating leukocyte-derived MV
levels might predict subclinical atherosclerosis in asymptomatic
individuals (12), and it was thus unexpected that the patients
did not have higher levels of CD14+ MVs, and that these
MV phenotypes were unaffected by inflammation. In
addition, we have previously demonstrated that patients
with familial hypercholesterolemia and thereby increased risk
of atherosclerosis, had higher levels of both CD14+ MVs
and CD14+CD36+ MVs compared to healthy controls (13).
Furthermore, other investigators demonstrated an association
between cardiovascular disease and increased CD14+ MVs
and total MV concentration (14, 15). One possible explanation
for our observations is that the patients in this study were
receiving pharmaceutical treatment including statins, which
may potentially reduce the MV concentration (16). Moreover,
age has been proposed to affect vesicle concentration with
decreasing number in advancing age (17). Since we were unable
to demonstrate any significant association of MV phenotypes
with age, it is unlikely that the reduced level of BLTR1+ MVs in
the atherosclerotic patient cohort can be attributed to increased
age compared to the healthy controls.
The AA-derived LTB4 has been linked to atherosclerosis
mainly through BLTR1 (8, 18) and a reduced concentration
of BLTR1+ MVs in the atherosclerotic patients was thus
unexpected. However, a number of studies (19, 20) have
demonstrated a chemotactic deactivation of leukocytes to LTB4,
which is attributed a diminished expression of BLTR1 by
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FIGURE 3 | Correlations of different MV phenotypes and arachidonic acid (AA) content. Correlations of (A) CD14+ MVs and AA in granulocytes, (B) CD14+CD36+
MVs and AA in granulocytes, and (C) CD14+CD36+ MVs and AA in plasma phospholipids. Nearly correlations of (D) CD14+ MVs and AA in plasma phospholipids
and (E) CD14+BLTR1+ MVs and AA in plaques. AA content in different compartments are measured in % of total fatty acids.
converting the high affinity BLTR1 to the low affinity BLTR2
and/or internalization of BLTR1 when exposed to LTB4. Chou
et al. (21) also documented a decreased BLTR1 expression
after leukocytes were exposed to LTB4 in infiltrated arthritic
joints. Atherosclerotic patients tend to have higher levels of
LTB4 than healthy controls (22) that could lead to a down-
regulation of the receptor and thus lower levels of BLTR1+
MVs in atherosclerotic patients, as found in the present study.
In relation to our findings of decreased CD14+BLTR1+ MVs,
Tangirala et al. (23) reported that differentiation frommonocytes
to macrophages by IFN-γ stimulation led to a rapid loss in
chemotactic response and further resulted in downregulation
of their chemotactic surface receptor by 40%. Pettersson
et al. (24) also demonstrated that pro-inflammatory cytokines
including TNF-α, IFN-γ, and LPS down-regulated BLTR1 surface
expression and mRNA expression in human monocytes opposed
to the anti-inflammatory cytokine IL-10 that up-regulated BLTR1
expression. In addition, they showed that the phenotypic pro-
inflammatory CD14+CD16+ monocytes had lower expression
of BLTR1 and CCR2 compared to the classical CD14++CD16−
monocytes expressing high levels of the receptors. In our study,
hsCRP levels were significantly higher in patients compared
to healthy controls. Moreover, there was a tendency toward
decreased CD14+CD36+BLTR1+ MVs, although not significant.
Therefore, it is likely that the chronic low-grade inflammatory
condition with abundance of the pro-inflammatory monocyte
phenotype in patients with femoral atherosclerosis together
with higher levels of LTB4 may further contribute to a down-
regulation of the BLTR1 and thus be in line with our findings of
reduced BLTR1+ MVs and CD14+ MVs.
In patients, we observed inverse correlations between levels
of CD14+ MVs and CD14+CD36+ MVs and AA in different
compartments. As previously described, CD36 on monocytes
enhances the atherosclerotic progression (4, 25–28) and is further
upregulated by LTB4 (11). Therefore, we would have expected
that the content of AA, the precursor for LTB4, was positively
correlated with the level of CD14+ MVs and CD14+CD36+
MVs but surprisingly this was not the case. It should be noted
that the major risk factor for femoral atherosclerosis is not
AA content but cigarette smoke (29), which might explain
the unexpected results. However, cigarette smoke is linked to
chronic inflammation and is found to increase the CD14+CD36+
cell population (30) thus most probably increasing the level of
CD14+CD36+ MVs. Importantly, the patients in the current
study were treated with aspirin (98%) and statins (96%) which
might lower the levels of CD36+ MVs andCD14+ MVs as studies
have demonstrated lower levels of sCD36 when treated with
acetylsalicylic acid (31) and several MV phenotypes, including
CD14+ MVs, when treated with statins (16). This may have
affected our results opposing what was expected.
Interestingly, we found that the level of CD14+ MVs and
CD14+CD36+ MVs correlated positively with triglyceride in
both patients and healthy controls, in accordance with the
function of CD36 as a fatty acid transporter. In previous studies,
we demonstrated similar associations in type 2 diabetic males
(32) and in severely obese individuals (unpublished results). The
lack of correlations between cholesterol fractions and MMVmay
be secondary to statin treatment and the resulting reduction of
total cholesterol and LDL as the primary effect, whilst there is
only minor impact on triglycerides (33).
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The current study has significant strength in several ways
despite its surprising results. To the best of our knowledge,
this study is the first to investigate BLTR1+ MVs and further,
the correlation between BLTR1+ MVs and the content of
EPA and AA in atherosclerotic patients. Thus, hypotheses
in this explorative study were based on clinical associations
and cell studies, which makes it more difficult to generate
precise hypotheses. Methodologically, flow cytometry is a high-
throughput method that holds the ability to simultaneously
characterize single MVs in regards to quantification, size
distribution, and expression of multiple surface markers, which
makes flow cytometry a preferred method in the study of MVs.
Nonetheless, traditional flow cytometers lack the ability to detect
the smallest MVs and have a lower cut-off limit of between 200
and 500 nm. We have developed a novel method for detection
of rare and small MV phenotypes, including BLTR1+ MVs,
utilizing a dedicated small-particle flow cytometer (spFCM) with
high sensitivity together with a novel data acquisition strategy
allowing detection of even very small and rare MVs. In addition,
this is the first study, using a spFCM that measures MVs directly
in plasmawithout purification, thus providing themost authentic
information of the mechanisms linked to development and
progression of the disease.
A number of limitations in this study should also be addressed.
First, the match between patients and controls is not optimal.
The big difference in age could have affected the level of several
MV phenotypes, which might explain the missing findings of
increased MV levels in patients that we would have expected.
However, it would be very difficult to find healthy controls with
the age of 70 years without plaque or other age-related diseases.
In addition, we found no significant correlation between age and
any of the investigated MV phenotypes. Further, the patients
in this study were receiving pharmaceutical treatment including
aspirin and statins. This has been shown to reduce the level
of several MV phenotypes including CD14+ and CD36+ MVs.
Although treatment of the patients is a limitation of the study,
atherosclerotic patients with such advanced disease that render
them suitable for thrombendarterectomy, and thereby plaque
characterization, are always receiving pharmacological treatment
hence this could most likely not have been avoided. Moreover,
we only have measurements of circulating LTB4, AA, and EPA
in patients and not in controls, which would have been desirable.
Lastly, MVs analyzed encompasses only monocyte-derived MVs
and not MVs derived from other cell types. As atherosclerosis
is a multifaceted disease, it would have been desirable further to
analyseMVs from platelets and especially endothelial cells among
others.
CONCLUSION
In summary, the present study demonstrated no differences
in the levels of total MVs, CD14+ MVs, CD36+ MVs,
and CD14+CD36+ MVs between patients and controls.
Furthermore, BLTR1+ MV phenotypes were significantly lower
in atherosclerotic patients compared to healthy controls and
CD14+ MVs and CD14+CD36+ MVs correlated inversely
with AA in granulocytes, and CD14+CD36+ with AA in
plasma phospholipids. These unexpected findings may be a
result of the confounding effects of pharmacologic treatment
of the atherosclerotic group. We did find a positive correlation
between the level of CD14+ MVs and CD14+CD36+ MVs
with triglyceride in both patients and healthy controls, which
is in accordance with the function of CD36 as a fatty acid
transporter. Since this is the first study of its kind, the results
are explorative and only indicative, and additional studies are
necessary to contribute to a more detailed understanding of the
relationship betweenMVs and the PUFA content in patients with
femoral atherosclerosis, and the potential of MVs as markers of
atherosclerosis pathophysiological mechanisms.
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